source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 18d ago↗ source
- Lycia Therapeutics raises $318 million in IPO to fund protein degrader programsLycia Therapeutics, a biotech focused on protein-degrading medicines, priced its initial public offering at about $318 million. The proceeds will be used to advance three LYTAC drug candidates, in…